March 26, 2017 4:11 PM ET

Biotechnology

Company Overview of 4d Molecular Therapeutics LLC

Company Overview

4d Molecular Therapeutics LLC researches and develops gene therapy products. It develops customized adeno-associated virus vectors to target specific tissues in the body while resisting neutralization by pre-existing antibodies. The company uses Directed Vector Evolution, a vector discovery platform to create customized gene delivery vehicles to deliver genes to any tissue or organ in the body. It develops its products for genetic diseases that involve target tissues in the areas of retina, heart, liver, brain, skeletal muscle, and lung. 4d Molecular Therapeutics LLC was founded in 2013 and is based in Emeryville, California.

5980 Horton Street

Suite 460

Emeryville, CA 94608

United States

Founded in 2013

Phone:

510-505-2680

Key Executives for 4d Molecular Therapeutics LLC

Co-Founder, Co-Chairman and Chief Executive Officer
Co-Founder, Co-Chairman and Acting Chief Scientific Officer
Co-Founder and Senior Vice President of Program & Alliance Management
Co-Founder, Head of AAV Research and Director
Controller
Age: 65
Compensation as of Fiscal Year 2016.

4d Molecular Therapeutics LLC Key Developments

4D Molecular Therapeutics Enrolls First Patient in Natural History Study in Lead Clinical Program to Develop Gene Therapy Treatment for Choroideremia

4D Molecular Therapeutics announced the enrollment of the first participant in its Choroideremia Natural History Study (NHS). This study is an important step in developing a gene therapy product optimized for intravitreal administration to treat Choroideremia (CHM) patients. 4DMT has deployed its proprietary AAV vector discovery platform, Therapeutic Vector Evolution, to create and optimize a proprietary AAV vector for intravitreal delivery to the retina. This vector is designated to be the basis for the first 4DMT experimental gene therapeutic targeted for the treatment of CHM. 4DMT is working in close collaboration with the Choroideremia Research Foundation on CHM product development and the Natural History Study. The NHS is a multi-center US-based study designed to evaluate disease progression in a wide variety of individuals with CHM. Understanding more about clinical endpoints as the disease progresses will aid in identifying both potential participants and the best clinical measures for upcoming 4DMT clinical trials. Participants in the study will be assessed periodically over two years. At each visit, they will undergo a series of photographic, imaging and clinical evaluations. Two clinical sites are actively recruiting for the study: Retina Foundation of the Southwest, Dallas, Texas (Principal Investigator Dr. David Birch). Retina Vitreous Associates of Los Angeles (Principal Investigator Dr. David Liao). Choroideremia is an X-linked retinal disease that begins as night blindness in childhood and progresses to complete blindness. It affects 1 in 50,000 people in the United States, predominantly males, and has no effective treatment.

4d Molecular Therapeutics LLC Presents at The Cell & Gene Meeting on the Mesa, Oct-05-2016 01:30 PM

4d Molecular Therapeutics LLC Presents at The Cell & Gene Meeting on the Mesa, Oct-05-2016 01:30 PM. Venue: La Jolla, CA 92037, United States. Speakers: Elizabeth Alcamo, Senior Director of Corporate Development.

4d Molecular Therapeutics LLC Presents at 4th Alliance for Regenerative Medicine Annual Cell and Gene Investor Day, Mar-22-2016 01:00 PM

4d Molecular Therapeutics LLC Presents at 4th Alliance for Regenerative Medicine Annual Cell and Gene Investor Day, Mar-22-2016 01:00 PM. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Speakers: David H. Kirn, Co-Founder, Co-Chairman, Chief Executive Officer and President.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact 4d Molecular Therapeutics LLC, please visit www.4dmoleculartherapeutics.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.